HighPoint Advisor Group LLC maintained its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,213 shares of the pharmaceutical company’s stock at the end of the 2nd quarter. HighPoint Advisor Group LLC’s holdings in GlaxoSmithKline PLC were worth $617,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC lifted its holdings in shares of GlaxoSmithKline PLC by 5.9% during the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after purchasing an additional 1,389,238 shares during the last quarter. Fisher Asset Management LLC lifted its stake in GlaxoSmithKline PLC by 4.7% in the 2nd quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after acquiring an additional 564,519 shares in the last quarter. Renaissance Technologies LLC lifted its stake in GlaxoSmithKline PLC by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares in the last quarter. Hotchkis & Wiley Capital Management LLC lifted its stake in GlaxoSmithKline PLC by 4.3% in the 2nd quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after acquiring an additional 322,700 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in GlaxoSmithKline PLC by 15.8% in the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after acquiring an additional 934,928 shares in the last quarter. 9.28% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently issued reports on GSK. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Friday, June 16th. Citigroup Inc. downgraded GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. BidaskClub downgraded GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, TheStreet downgraded GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $44.67.
TRADEMARK VIOLATION WARNING: This report was first published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thestockobserver.com/2017/10/13/highpoint-advisor-group-llc-has-617000-position-in-glaxosmithkline-plc-gsk.html.
Shares of GlaxoSmithKline PLC (GSK) traded down 0.1368% on Friday, reaching $40.9639. The company’s stock had a trading volume of 2,338,116 shares. The stock has a market cap of $100.12 billion, a PE ratio of 39.6937 and a beta of 1.03. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.54. The company’s 50 day moving average is $40.28 and its 200-day moving average is $41.59.
GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, October 12th. Investors of record on Friday, August 11th were issued a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a yield of 4.79%. The ex-dividend date of this dividend was Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is presently 198.00%.
GlaxoSmithKline PLC Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.